Who Owns Kymera Therapeutics Stock?
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 116.67%
- Institutions (% of float)
- 120.56%
- Held by insiders
- 3.22%
- Institutional holders
- 427
- Institutions 96.8%
- Insiders 3.2%
- Public and other 0.0%
Who owns Kymera Therapeutics stock?
Institutional investors own about 116.7% of Kymera Therapeutics's shares, spread across 427 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.22% of KYMR.
The largest institutional holders are FMR, LLC (14.72%), Baker Bros. Advisors, LP (10.14%) and Avoro Capital Advisors LLC (8.76%). Together, the top 10 institutions control 72.0% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their KYMR positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of KYMR
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 12.57M | 14.72% | +1.8% |
| Baker Bros. Advisors, LP | 8.66M | 10.14% | 0.0% |
| Avoro Capital Advisors LLC | 7.47M | 8.76% | 0.0% |
| Price (T.Rowe) Associates Inc | 7.11M | 8.33% | +17.4% |
| T. Rowe Price Investment Management, Inc. | 6.26M | 7.33% | +14.5% |
| Blackrock Inc. | 5.83M | 6.82% | +5.2% |
| BVF Inc. | 3.87M | 4.54% | -29.6% |
| Wellington Management Group, LLP | 3.68M | 4.30% | -5.5% |
| Vanguard Capital Management LLC | 3.04M | 3.57% | +3.8% |
| Vanguard Portfolio Management LLC | 2.98M | 3.49% | -0.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of KYMR
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.28M | 2.67% |
| T. Rowe Price New Horizons Fund, Inc. | 2.26M | 2.64% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.09M | 2.45% |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.05M | 2.40% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.80M | 2.10% |
| iShares Trust-iShares Russell 2000 ETF | 1.62M | 1.90% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.51M | 1.77% |
| SmallCap World Fund Inc | 1.32M | 1.54% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.07M | 1.25% |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 1.02M | 1.19% |
Frequently asked questions
Who is the largest shareholder of Kymera Therapeutics?
FMR, LLC is the largest institutional shareholder of KYMR, owning 14.72% of shares outstanding (12.57M shares) as of its latest 13F filing.
What percentage of Kymera Therapeutics is owned by institutions?
Institutions own about 116.7% of KYMR shares and 120.6% of the public float.
How much of Kymera Therapeutics do insiders own?
Insiders, such as officers and directors, own about 3.22% of KYMR shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.